Neuroimaging in Drug Discovery and Development: Paradigms for Accelerating New Drug Availability

Abstract

The process of discovering and developing new drugs is complicated. Neuroimaging methods can facilitate this process. An analysis of the conceptual bases and practical limitations of different neuroimaging modalities reveals that each technique can best address different kinds of questions. Radioligand studies are well suited to preclinical and Phase II questions when a compound is known or suspected to affect well-understood mechanisms; they are also useful in Phase IV to characterize effective agents. Cerebral blood flow studies can be extremely useful in evaluating the effects of a drug on psychological tasks (mostly in Phase IV). Glucose metabolism studies can answer the simplest questions about whether a compound affects the brain, where, and how much. Such studies are most useful in confirming central effects (preclinical and early clinical phases), in determining effective dose ranges (Phase II), and in comparing different drugs (Phase IV).

Keywords

positron emission tomography (PET)functional magnetic resonance imaging (fMRI)drug development cerebral blood flow cerebral glucose metabolism

Get full access to this article

View all access options for this article.

References

Myshko D. On the right track. R&D Directions.1996; 2:22.

DiMasi JA , Hansen RW , Grabowski HG , et al . Research and development costs for new drugs by therapeutic category. Pharmacoeconomics.1995;7:152-169.

Laven DL , Bednarcyzk EM . CNS assessment using functional neuro-PET imaging. J Pharm Pract.2001; 14:308-331.

Toga AW , Mazziotta JC . Brain Mapping: The Methods. 1996.

Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci.1996; 19:211-214.

Nyberg S , Eriksson B , Oxenstierna G , et al . Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry.1999; 156:869-875.

Lammertsma AA . Positron emission tomography and in vivo measurements of tumour perfusion and oxygen utilisation. Cancer Metast Rev. 1987; 6:521-539.

Katz PS , Clemens S. Biochemical networks in nervous systems: expanding neuronal information capacity beyond voltage signals. Trends Neurosci.2001; 24:18-25.

Roy CS , Sherrington CS . On the regulation of the blood supply of the brain. J Physiol (London). 1890; 11:85-108.

10.

Kety SS , Schmidt CF . The determination of cerebral blood flow in man by the use of nitrous oxide in low concentrations. Am J Physiol. 1945; 143:53-66.

11.

Raichle ME , Posner M. Images of Mind: Exploring the Brain’s Activity. 1994.

12.

Ogawa S , Lee TM . Magnetic resonance imaging of blood vessels at high fields: In vivo and in vitromeasurements and image simulation. Magnetic Resonace in Medicine. 1990; 16:9-18.

13.

Tracey I. Pharmacological FMRI: a new tool for drug development in humans. J Pharm Pract. 2001; 14:368-375.

14.

Cooper MD , Metz JT , Kalbhen C , et al . Metabolic characterization of brain states: Opposing effects of partial sensory limitation on left and right brain responses. J Nucl Med. 1989; 30 (Suppl):899.

15.

Theodore WH . Antiepileptic drugs and cerebral glucose metabolism. Epilepsia. 1988; 29 (Suppl 2): S48-S55.

16.

Sokoloff L. Basic principles in imaging of regional cerebral metabolic rates. Res Publ Assoc Res Nerv Ment Dis. 1985; 63:21-49.

17.

Fox PT , Raichle ME . Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci USA. 1986; 83:1140-1144.

18.

Katz PS . Beyond Neurotransmission: Neuromodulation and Its Importance for Information Processing. New York: Oxford University Press,1999.

19.

Cooper M , Metz J , de Wit H , et al . Interclass drug effects and changes in regional brain glucose metabolism. Psychopharm Bull. 1998; 34:229-232.

20.

Cook EH , Metz J , Leventhal BL , et al . Fluoxetine effects on cerebral glucose metabolism. NeuroReport.1994; 5:1745-1748.

21.

Metz JT , Colasante DA , Brown TF , et al . Effects of Premarin® and Evista® on cerebral metabolism of glucose in healthy postmenopausal women. North American Menopause Society (NAMS). 1999.

22.

Metz J , Cooper M , Brown T , et al . Quantitative functional imaging (FDG-PET) and intra-class drug effects. Symposium on the Use of Imaging in Drug R&D. 2000.

23.

Brown TF , Cooper M , Metz J , et al . Metabolic imaging for dose evaluation in clinical trials: proof of principle. Symposium on the Use of Imaging in Drug R&D. 1998.